Therefore, durvalumab is the first and only anti-PD-1/PD-L1 ICI authorized for consolidation therapy in post-chemoradiotherapy and unresectable stage III NSCLC patients. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.